MarketCap
Facebook
X
Telegram
PainReform Ltd. Net Debt | PRFX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt PainReform Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -7.94 M | - | - | -15.7 M | 5.23 M | 4.48 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.23 M | -15.7 M | -3.48 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Prothena Corporation plc
PRTA
|
-299 M | $ 8.56 | -2.51 % | $ 461 M |  USA |
 |
Arcus Biosciences
RCUS
|
-110 M | $ 18.66 | -1.56 % | $ 2 B | USA |
 |
Orgenesis
ORGS
|
157 K | - | -33.86 % | $ 61.2 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
-2.05 B | $ 14.9 | -1.03 % | $ 12.4 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
-1.09 B | $ 916.16 | -0.41 % | $ 95.8 B | USA |
 |
Replimune Group
REPL
|
-125 M | $ 23.3 | 4.67 % | $ 2.16 B | USA |
 |
Фармсинтез
LIFE
|
612 M | - | - | - |  Russia |
 |
Royalty Pharma plc
RPRX
|
8.33 B | $ 69.47 | 1.02 % | $ 29.9 B | USA |
 |
Revolution Medicines
RVMD
|
-225 M | $ 193.0 | -3.57 % | $ 36.7 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
47.2 M | $ 113.99 | 0.04 % | $ 7.41 B | USA |
 |
Codiak BioSciences
CDAK
|
-39.4 M | - | -55.98 % | $ 2.15 M | USA |
 |
Sana Biotechnology
SANA
|
6.99 M | $ 2.43 | -1.42 % | $ 615 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-10 M | $ 61.81 | 0.11 % | $ 172 M |  Israel |
 |
Summit Therapeutics
SMMT
|
-204 M | $ 17.78 | -0.34 % | $ 13.3 B |  Britain |
 |
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-152 M | $ 9.43 | -0.89 % | $ 817 M | USA |
 |
Spero Therapeutics
SPRO
|
-37.4 M | $ 1.01 | -5.61 % | $ 56.6 M | USA |
 |
Sarepta Therapeutics
SRPT
|
38.9 M | $ 16.4 | -5.54 % | $ 1.64 B | USA |
 |
Tarsus Pharmaceuticals
TARS
|
-111 M | $ 73.9 | 4.32 % | $ 3.09 B | USA |
 |
Bio-Techne Corporation
TECH
|
-49.8 M | $ 72.83 | -0.01 % | $ 11.4 B | USA |
 |
Sage Therapeutics
SAGE
|
-69.2 M | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
-513 M | - | - | $ 1.62 B | Israel |
 |
Cabaletta Bio
CABA
|
-76.6 M | $ 1.43 | -5.0 % | $ 144 M | USA |
 |
Forma Therapeutics Holdings
FMTX
|
-44.7 M | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-19.9 M | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
202 M | - | - | $ 26.6 B |  Irlanda |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-206 M | $ 4.12 | -8.35 % | $ 35.1 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
223 M | - | - | $ 121 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-188 M | $ 11.55 | 4.52 % | $ 1.61 B |  France |
 |
Gilead Sciences
GILD
|
14.7 B | $ 170.68 | 0.8 % | $ 212 B | USA |
 |
Taysha Gene Therapies
TSHA
|
-268 M | $ 4.28 | -2.06 % | $ 1.37 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-13.8 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
16 M | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-137 M | - | - | $ 411 M | USA |
 |
Gossamer Bio
GOSS
|
-33.3 M | $ 11.2 | 5.21 % | $ 2.56 B | USA |
 |
GeoVax Labs
GOVX
|
-2.24 M | $ 0.11 | -22.17 % | $ 105 K | USA |
 |
United Therapeutics Corporation
UTHR
|
112 M | $ 588.33 | 1.01 % | $ 26.1 B | USA |
 |
Seelos Therapeutics
SEEL
|
11.2 M | - | -47.76 % | $ 6.27 M | USA |
 |
Vericel Corporation
VCEL
|
-85.6 M | $ 59.02 | 1.08 % | $ 2.97 B | USA |
 |
Veracyte
VCYT
|
-323 M | $ 24.05 | -7.21 % | $ 1.89 B | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
GlaxoSmithKline plc
GSK
|
-2.57 B | $ 51.25 | -0.56 % | $ 208 B | Britain |
 |
Vir Biotechnology
VIR
|
-134 M | $ 13.17 | -3.48 % | $ 1.82 B | USA |
 |
Viking Therapeutics
VKTX
|
-25.6 M | $ 28.67 | -1.1 % | $ 3.23 B | USA |
 |
Vanda Pharmaceuticals
VNDA
|
-78.6 M | $ 4.07 | -0.49 % | $ 240 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-15 M | $ 3.55 | -1.11 % | $ 37.8 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
-4.9 B | $ 547.74 | -0.57 % | $ 140 B | USA |
 |
Kiromic BioPharma
KRBP
|
-224 K | - | 6.61 % | $ 3.08 M | USA |